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Conclusions. FSGS may belong to the spectrum of renalClinical and pathologic features of focal segmental glomerulo-
involvement in A3243G mtDNA mutation in humans. Severelysclerosis with mitochondrial tRNALeu(UUR) gene mutation.
injured podocytic changes containing abnormal mitochondriaBackground. Several families have been described in which
may explain the pathogenesis of FSGS in association with thean A to G transition mutation at position 3243 (A3243G) of
A3243G mtDNA mutation.the mitochondrial DNA (mtDNA) is associated with focal and
segmental glomerulosclerosis (FSGS). However, the preva-
lence, clinical features, and pathophysiology of FSGS carrying
mtDNA mutations are largely undefined.
An A to G transition at position 3243 in mitochondrialMethods. Among 11 biopsy-proven primary FSGS patients
DNA (mtDNA) has been described mainly in associa-of unknown etiology, we examined seven FSGS patients to
determine whether any of the clinical and pathological features tion with mitochondrial myopathy, encephalopathy, lac-
of FSGS were associated with an A3243G mtDNA mutation. tic acidosis, and stroke-like episodes (MELAS) or pro-
In four subjects in whom the A3243G mtDNA mutation was
gressive external ophthalmoplegia (PEO) [1]. Althoughdiscovered in blood leukocytes, as well as in urine sediments,
the central nervous system and striated muscle seem towe retrospectively reviewed the medical records and re-evalu-
ated the renal biopsy specimen using light and electron micros- be especially vulnerable in these syndromes, patients
copy. We further screened the patient’s family members for may also have atypical presentations suggestive of an
the presence and degree of heteroplasmy for this mtDNA
involvement of other organs or tissues. Diabetes mellitus,mutation and obtained medical histories that were consistent
hearing loss, and cardiomyopathy are well known aswith mitochondrial cytopathy.
Results. The four individuals identified with the A3243G uncommon manifestations of the A3243G mutation
mtDNA mutation were female. Proteinuria was diagnosed in [1, 2]. Renal tubular dysfunctions, including de-Toni-
these individuals during a routine annual health checkup in Debre´-Fanconi syndrome, or renal tubular acidosis, havetheir teenage years. None of the patients showed any symptoms
also been described as rare symptoms in late stages ofrelated to mitochondrial myopathy, encephalopathy, lactic aci-
dosis, and stroke-like episode, whereas diabetes mellitus in two MELAS [3].
of the patients and a hearing disturbance in one patient became Recently, focal and segmental glomerulosclerosis
manifest within a 3- to 13-year follow-up period. Strict maternal (FSGS) has been attracting attention as an unusual phe-transmitted inheritance was confirmed by pedigree studies in
notype of mitochondrial cytopathy carrying the A3243Gall of these patients. Steroid therapy was ineffective in all four
patients. In two of these patients, renal function declined slowly mutation. In some patients, FSGS was eventually found
to end-stage renal failure. Histologic examination of biopsy spec- during a follow-up period for MELAS [4], whereas in
imens revealed that glomeruli were not hypertrophied, while other patients, FSGS was diagnosed even before charac-electron microscopic examination identified severely damaged,
teristic signs and symptoms of MELAS became apparentmultinucleated podocytes containing extremely dysmorphic
[3]. On the other hand, Jansen et al have described fourabnormal mitochondria in all patients.
cases of progressive nondiabetic kidney disease in associ-
ation with the A3243G mutation, in which none of theseKey words: DNA mutation, A3243G transition mutation, podocyte,
MELAS, proteinuria, kidney glomeruli, FSGS. patients expressed MELAS or PEO during a follow-up
period for over 5 to 17 years. In addition, biopsy-proven
Received for publication January 20, 2000
FSGS was confirmed in two of these patients [5]. Kuro-and in revised form September 5, 2000
Accepted for publication October 20, 2000 gouchi et al have also reported a case of mitochondrial
cytopathy manifested as FSGS, but not as MELAS [6].Ó 2001 by the International Society of Nephrology
1236
Hotta et al: FSGS and mtDNA mutation 1237
All of these reports suggest that FSGS may be a new ogy (for example, Alport’s syndrome) were all ruled out
to the fullest extent possible based on both clinical andphenotypical expression in the broad clinical spectrum
associated with the A3243G mtDNA mutation. histologic findings. Ancillary factors supporting the diag-
nosis of FSGS, including the detection of focal, segmentalHowever, hitherto, the pathological changes in kidney
glomeruli in FSGS patients carrying the A3243G mtDNA glomerular staining for immunoglobulin M, and/or C3 by
immunofluorescence microscopy, were confirmed. Glo-mutation have not been studied as in much detail as the
mtDNA mutation in the striated muscle and the central merular volume was determined on light microscopic
sections, as described previously [8]. Markedly deformednervous system of MELAS patients. Both the prevalence
and the clinical features of this putative atypical pheno- or globally sclerotic glomeruli were not included in the
calculation.type of mitochondrial cytopathy remain to be clarified.
The present study reviews our experience in diagnosing
Molecular studiesfour FSGS patients possessing the A3243G mtDNA mu-
tation and their treatment period of 3 to 15 years. We DNA was isolated from peripheral blood leukocytes,
as well as from urine sediments obtained from 3 to 50have also studied the pathological changes of the affected
kidneys in these patients in detail, and found severely mL of voided urine, using a commercially available DNA
isolation kit (Sepa Genet; Sanko Pharmaceutical Co.,damaged podocytic changes containing extraordinary
dysmorphic mitochondria, which may participate in the Tokyo, Japan). Six types of mtDNA mutations, including
A3243G, T3250C, A3252G, C3256G, T8993C, and T8993Gdevelopment of FSGS.
[9], were screened in the extracted DNA samples. Poly-
merase chain reaction (PCR) amplification of the mtDNA
METHODS
fragments encompassing the 3243 point mutation was per-
Patients and histologic studies formed using the following two oligonucleotide primers:
59-AGGACAAGAGAAATAAGGCC-39 (3130 to 3149)Between 1978 and 1997, out of 4227 renal biopsied
patients, 68 patients were histopathologically diagnosed and 59-AAGAGCGATGGTGAGAGCTA-39 (3555 to
3536). Cycling conditions applied for amplification werewith FSGS, based on the criteria of Churg, Habib, and
White [7]. Among these patients, 46 patients were ne- 948C for 30 seconds, 508C for 30 seconds, and 728C for
30 seconds, for a total of 30 cycles. Approximately 1 mgphrotic. Out of the 22 non-nephrotic patients, four pa-
tients were diagnosed with secondary FSGS caused by of the PCR product was digested with 54 units of Apa I
for 24 hours, and restriction fragments were separated byhypertensive nephrosclerosis. Four patients were diag-
nosed with reflux nephropathy, 2 patients were massively 3% agarose gel electrophoresis, followed by visualization
with double-stranded DNA-specific dye, SYBR Green Iobese, and 2 patients had hypoplastic kidneys. The other
10 patients in this FSGS group were diagnosed pathologi- (Molecular Probes, Eugene, OR, USA). With this method,
the recognition site for the restriction endonuclease Apa Ically with FSGS without nephrotic syndrome of un-
known etiology. Since 7 out of these 10 patients kept detected the A!G mutation at position 3243 of the
mtDNA. Quantitative analysis of the mutated and wild-visiting our out-patient clinic, we performed mtDNA
mutation analyses in these patients after obtaining in- type mtDNA was done using an isotope-labeled primer,
as previously described [10]. A good correlation wasformed consent. Diseases known to be associated with
FSGS, including sickle cell disease, human immunodefi- observed between the degree of heteroplasmy obtained
with this method and that with the quantitation of theciency virus infection, intravenous drug use, and urinary
tract obstruction, were excluded in all seven patients. In Apa I generated restriction fragments stained by SYBR
Green I [11] using a fluoroimage analyzer (FLA 2000;addition, we screened several types of mtDNA mutations
and identified an A3243G mtDNA mutation in four of r 5 0.90, P , 0.05; Fujifilm, Tokyo, Japan).
these patients. We retrospectively reviewed the medical
Data analysisrecords of these four patients and re-examined in detail
the renal biopsy specimens using light and electron mi- Data were presented as mean 6 SD and were analyzed
by an unpaired Student t test. A value of P , 0.05 wascroscopy, as described [7].
The histologic diagnosis of FSGS by kidney biopsy considered statistically significant.
was based on the presence of areas of glomerular scarring
and tuft collapse that were both focal (involving only
RESULTS
a subpopulation of glomeruli) and segmental (sparing
Identification of the mutationportions of involved glomeruli). Possible underlying
causes of segmental glomerulonephritis [for example, Four FSGS patients had an A3243G mutation in the
mtDNA obtained from both peripheral blood leuko-immune complex deposition, antiglomerular basement
membrane (anti-GBM) antibodies and vasculitis] and cytes and urinary sediments. The other three patients
did not possess any of the mitochondrial mutations, in-other potential causes of segmental glomerular pathol-
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patient 4 was found to have proteinuria, she noticed
hearing disturbance. None of the patients nor family
members showed stroke-like episodes or myopathy dur-
ing the follow-up period. All four patients were rather
short in stature for Japanese women (22.98 to 20.38
SD of mean value),
At the time of renal biopsy, all patients showed normal
blood pressure. None of the patients exhibited nephrotic
syndrome, and the 24-hour urinary protein excretion
ranged from 1.0 to 1.6 g. Urinary b2-microglobulin (b2m)
concentration, which was examined in three patients,
was within normal levels (Table 1). Renal function, de-
fined by creatinine clearance level, was mildly impairedFig. 1. Identification of an A to G mutation at position 3243 in mito-
in all patients except patient 2. During a follow-up pe-chondrial DNA. DNA samples were isolated from peripheral blood
leukocytes (B) and from urine sediments (U). Fragments of mitochon- riod, patients 2 and 4 showed a decline in renal function.
drial DNA encompassing position 3243 were obtained by PCR, digested At 35 years of age, 20 years after the onset of nephropa-with Apa I, separated using agarose gel (3%) electrophoresis, and
thy, patient 4 reached end-stage renal failure and re-stained with SYBR Green I. Affected subjects are heteroplasmic for
the mutation. Urine sediment of normal adult was analyzed as control. quired regular dialysis treatment.
M, molecular weight marker. At the time of renal biopsy, none of the patients had
overt diabetes mellitus, although a 75 g oral glucose
tolerance test (75 g OGTT) was impaired in patients 2
and 4. Predonisolone steroid therapy was ineffective including A3243G, T3250C, A3252G, C3256G, T8993C,
all four patients. In addition, patient 4 developed overtand T8993G [9]. Figure 1 shows the restriction fragment
diabetes mellitus following steroid therapy; thereafter,length polymorphism analysis of the digested PCR-
she needed insulin injections to maintain her blood glu-amplified mtDNA fragment with Apa I, demonstrating
cose levels. Five years following the diagnosis of FSGS,that these subjects are heteroplasmic for this mutation.
patient 2 developed overt diabetes mellitus in the eighthThe mitochondrial mutation was also examined in some
month of her first pregnancy, but she had a full-termof the family members of these four patients, demonstra-
delivery without any complications. The other two pa-ting that FSGS was cosegregated with the mutation in
tients (patients 1 and 3) did not develop overt diabetesa fashion consistent with maternal transmission. In all
mellitus during the follow-up period.of the subjects tested, the prevalence of this mtDNA
mutation was higher in urine sediments than in periph- Histologic examination of renal tissues
eral blood leukocytes (Fig. 2). Moreover, we analyzed
All biopsy specimens were obtained by surgical needle
mtDNA mutations using urine sediments in 25 patients
biopsy. In patient 3, renal biopsies were performed twice
out of 46 nephrotic FSGS patients. In this comparative in the nine-year follow-up period. The histologic changes
study, we did not find any type of mtDNA mutations, are tabulated in Table 2. On light microscopy, the histol-
including A3243G. ogy findings were compatible with FSGS [7] (Fig. 3), but
at the time of diagnosis, all of the patients had only mildClinical history
histologic changes: They showed between 0 and 20.0%
The pedigrees of four patients within three families obsolute glomeruli, 4.3 to 7.1% segmental sclerosis, only
are shown in Figure 2. The clinical characteristics of focal tubular interstitial atrophy or fibrosis, and no vascu-
patients with FSGS carrying the A3243G mutation are lar changes. In the second biopsy of patient 3, the propor-
summarized in Table 1. All four patients were female tion of globally sclerotic glomeruli and segmentally scle-
and included two sisters (patients 2 and 3). All showed rotic glomeruli increased to 53.3 and 20.0%, respectively,
ambiguous onset of the disease since asymptomatic pro- as did the interstitial fibrotic area (Table 2).
teinuria was first detected during a routine annual health Then, the values of mean glomerular volume (MGV)
checkup when they were between 10 and 17 years old. in patients diagnosed with the FSGS carrying the
Microhematuria was absent in all four patients. The A3243G mtDNA mutation were compared with MGV
mothers of patients 2, 3, and 4 had diabetes mellitus. values of other FSGS patients. As shown in Figure 4,
The mother of patient 4 was also suffering from hearing mean MGV in FSGS patients carrying the mtDNA muta-
disturbance, and a female cousin had chronic renal fail- tion was 3.45 6 0.44 3 106 mm3 (N 5 5), which is not
ure, diabetes mellitus, and hearing disturbance. The significantly different from those of the control popula-
older brother of patient 1 had also been diagnosed with tion of minor glomerular abnormalities [8]. On the other
hand, the MGV values were significantly increased indiabetes mellitus. At 24 years of age, nine years after
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Fig. 2. Family trees of four patients diagnosed with focal segmental glomerulosclerosis (FSGS) and carrying the A3243G mutation. Percentages
represent the population of mitochondrial mutation detected by restriction fragment length polymorphism analyses of the digested PCR-amplified
mtDNA fragment with Apa I in peripheral blood leukocytes (B) and in urinary sediments (U). Symbols are: (d) proteinuria positive; (*) diabetes
mellitus; (3) hearing disturbance; (m) hemodialysis.
primary nephrotic FSGS (4.96 6 0.84 3 106 mm3, N 5 mtDNA mutation was identified in peripheral blood leu-
kocytes as well as in urine sediments. In these patients,11, P , 0.01) or secondary FSGS patients (12.13 6 3.63 3
106 mm3, N 5 6, P , 0.001) compared with those in FSGS typical manifestations of the MELAS syndrome were
absent. Instead, diabetes mellitus in two patients andpatients carrying the mtDNA mutation.
hearing disturbance in one patient became manifest dur-Each biopsy specimen was examined further in detail,
ing routine follow-up periods, which is compatible withand we found that glomerular podocytes were in the
mitochondrial cytopathy. The clinical features in thesecenter of the pathological lesions. The podocytes were
patients share several common characteristics with thosedamaged (some of them severely). Typical podocytic
described by Jansen et al, in which the authors describechanges consisted of cell body attenuation together with
four patients harboring the A3243G mtDNA mutationpseudocyst formation and foot process effacement (Fig.
and manifesting FSGS with occasionally complicated hear-5). Binucleated or multinucleated podocytes generally
ing disturbance and diabetes mellitus, but not MELASexhibited severe lesions in all four patients (Figs. 5–7A).
[5]. The similarities between our present study and thatWithin the cytoplasm of the podocytes, a marked in-
of Jansen et al include the following: (1) the onset ofcrease in the number of mitochondria with striking fea-
proteinuria is ambiguous at a young age (mean age oftures were observed, including variation in size and
16 years in the present report vs. 26 years in Jansen’sshape, irregular outline, increase of cristae, and lamellar
report); (2) long-standing hypertension is absent in thestructures. Swollen mitochondria often lost the arrange-
early stages of the disease; (3) only hearing disturbancement of cristae (Fig. 7B). Paracrystalline inclusions
and diabetes mellitus are symptoms consistent with mito-within mitochondria were not found. It should be noted
chondrial cytopathy; and (4) none of the probands northat the degree of accumulation of abnormal mitochon-
their family members have had episodes of MELAS syn-dria varied among the glomeruli and podocytes, and that
drome. Considering these similarities, it is tempting tothese mitochondrial abnormalities were virtually absent
suggest that the phenotypical expression of FSGS, whichin mesangial cells as well as in capillary endothelial cells.
can be complicated by hearing disturbance and diabetesChanges in the GBM, including thickening and thinning
mellitus, may be classified as a new subtype of mitochon-of GBM, lamellation, and fragmentation of the lamina
drial cytopathy harboring the A3243G mutation, as hasdensa, suggesting Alport’s syndrome, were absent in all
been proposed by Jansen et al [5].cases. On the other hand, tubular epithelial cells showed
Pathological analyses of renal biopsy specimens inan accumulation of abnormal mitochondria in both prox-
these four patients offer important insights into theimal and distal tubules (Fig. 8).
mechanism of the development of FSGS in patients car-
rying the A3243G mtDNA mutation. The podocytes
DISCUSSION seen in our cases were essentially similar to those re-
Our study examined four patients who were first diag- ported in idiopathic FSGS and demonstrated cell body
attenuation, pseudocyst formation, and foot process ef-nosed with FSGS, and thereafter a heteroplasmic A3243G
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facement [12]. Frequent occurrence of binucleated and
multinucleated podocytes, the hallmark of severely dam-
aged podocytes [13], was also observed (Figs. 5–7A).
However, within the podocytes, accumulation of numer-
ous dysmorphic mitochondria was prominent in FSGS
patients with the A3243G mtDNA mutation (Fig. 7B).
It should be noted that in these specimens, abnormal
mitochondria were exclusively accumulated in podo-
cytes, whereas both mesangial cells and capillary endo-
thelial cells in glomeruli appeared intact. Since podocytes
are highly differentiated terminal cells that do not un-
dergo cell division in the postnatal period [14], it is sug-
gested that podocytes may be susceptible to the accumu-
lation of mutated mitochondria such as in neural and
muscle cells. Then, because of the accumulation of these
abnormal mitochondria, mitochondrial protein synthesis
and energy supply may be impaired [15], leading to the
induction of podocytic dysfunction followed by develop-
ment of FSGS.
Of interest is the differences of MGV values in FSGS
specimens with the A3243G mtDNA mutation in com-
parison with other types of FSGS specimens (Fig. 4).
The MGV values obtained from patients diagnosed with
FSGS containing the mtDNA mutation were close to
those of the control population group [8], whereas pri-
mary nephrotic or secondary FSGS patients exhibited
significantly greater MGV values. Recently, Fogo et al
have suggested that glomerular hypertrophy can play
a crucial role in the pathogenesis of human FSGS by
demonstrating that glomerular size in patients with pri-
mary FSGS is significantly larger than that of cases with
minimal lesion [16]. In light of Fogo’s hypothesis, the
absence of glomerular enlargement in patients of FSGS
carrying the mtDNA mutation and given that MGV did
not change significantly during the clinical and histologic
progression of FSGS in patient 3 suggests that at least
glomerular hypertrophy may not be involved in the
pathogenetic mechanisms in developing or progressing
mitochondrial cytopathic FSGS.
Our diagnostic setup, consisting of DNA samples pre-
pared from the sediments of voided urine followed by
the detection of the A3243G mutation using PCR tech-
niques, is an effective way to identify the mutation of
mtDNA. In our study of all of the FSGS patients harbor-
ing the A3243G mutation, the proportions of mutant
DNA in urine sediments were higher than those in pe-
ripheral blood leukocytes. We even experienced an indi-
vidual in whom peripheral blood leukocytes did not yield
evidence of the mtDNA mutation, although the mutation
was detectable in urine sediments (the mother of patient
1). The reason for this higher ratio of mutant-to-normal
type mtDNA in urine sediments has not been fully ana-
lyzed. However, urine sediments contain twice as many
renal tubular epithelial cells than leukocytes [17]. As
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shown in the present study, tubular epithelial cells tend
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Table 2. Histopathological findings
Patient Number of Global Segmental Tubulointerstitial Vascular
number glomeruli sclerosis sclerosis changes changes
1 14 0 (0%) 1 (7.1%) Focal —
2 20 0 (0%) 1 (5.0%) Focal —
3a 23 3 (13.0%) 1 (4.3%) Focal —
15 8 (53.3%) 3 (20.0%) Diffuse —
4 20 4 (20.0%) 1 (5.0%) Focal —
a Note, histopathological findings were examined twice
Fig. 5. Electron microscopic view of a podocyte in kidney tissue ob-
Fig. 3. Light microscopic view of a kidney biopsy specimen obtained tained from patient 1. Binucleated podocyte with vacuolar degeneration
from patient 4 revealing a segmentally sclerotic lesion (3400). and widespread foot process effacement can be seen in this specimen
(35000).
Fig. 6. Electron microscopic view of a podocyte in kidney tissue ob-
tained from patient 2. Binucleated podocyte with dark staining absorp-
tion droplets can be seen in this specimen (34000).
to accumulate abnormal mitochondria (Fig. 8), whereasFig. 4. Mean glomerular volume (MGV) in FSGS patients carrying the
A3243G mtDNA mutation compared with those patients with primary heteroplasmic leukocytes possessing a high mitotic index
FSGS or secondary FSGS. The horizontal bars indicate the median tend to be selected over the course of many generationsvalues. In patients with FSGS harboring the A3243G mtDNA mutation
of cell division [18], suggesting that the tubular epithelial(A3243G-FSGS), the values were calculated using five biopsy specimens
obtained from four patients. Primary FSGS patients were all nephrotic cell component of urine sediments may contribute to
(N 5 11), whereas patients with secondary FSGS (N 5 6) were diag- increases in the amount of mutated mtDNA in urinenosed with hypoplastic kidney (N 5 2), reflux nephropathy (N 5 3),
and massive obesity (N 5 1), respectively. sediments. Although podocytes have recently been iden-
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Fig. 7. Electron microscopic view of podocytes in renal glomerulus in patient 2. Binucleated podocyte with foot process reaching to the GBM is
observed in this specimen (34000; A). Higher magnification of the abnormal podocyte reveals a markedly increased number of abnormal
mitochondria of varied sizes and shapes. Swollen mitochondria show disarrangement of cristae (330,000; B).
In conclusion, we reviewed the clinical features of four
cases of familial FSGS harboring the A3243G mtDNA
mutation and demonstrated that non-nephrotic FSGS is
the characteristic feature at least in the early phase of
the disease. We also suggested the causative role of the
accumulation of abnormal mitochondria in podocytes.
The overall incidence of A3243G mtDNA mutation in
patients with asymptomatic proteinuria or in nephrotic
FSGS patients is unknown. Since individuals with
A3243G mtDNA mutation are often asymptomatic or
oligosymptomatic, it can be assumed that the underlying
mitochondrial cytopathy is present in a certain popula-
tion of individuals with asymptomatic proteinuria as well
as of familial or sporadic FSGS. We suggest that theFig. 8. Electron microscopic view of renal tubular epithelial cells in
recognition of this mitochondrial mutation will be clini-patient 2. Proximal tubular epithelial cells with microvilli had increased
the number of dysmorphic mitochondria containing disoriented cristae. cally important in FSGS patients in order to avoid useless
Note that abnormal mitochondria are prominent on the right side of administration of steroids, which may potentially accel-the cell (38000).
erate the onset of diabetes mellitus.
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